Table 1

Demographic and clinical data of the three patients with general paresis at first evaluation

Patient 1Patient 2Patient 3
Age434238
History of cognitive decline4 months8 months4 months
Neuropsychological examinationSpeech fluency and verbal and spatial impairment; MMSE 24/30Dysexecutive syndrome with deficit of selective attention, cognitive flexibility, encoding and recalling of information in long term memory; MMSE 21/30Speech fluency and verbal impairment; deficit of encoding and recalling of information in long-term memory
Neurological examinationMild bilateral slowing in pupil response to light and accommodationDysarthria, sporadic phonemic paraphasia, sensory ataxia, hyperactive tendon reflexesMild impairment in motor coordination
Blood testsTPHA pos 1:10 240; IgG FTA-ABS pos; IgM FTA-ABS pos; RPR posTPHA pos 1:5120; IgG FTA-ABS pos; IgM FTA-ABS neg; RPR posTPHA pos 1:5120; IgG FTA-ABS pos; IgM FTA-ABS pos, RPR neg
CSF tests22 WBC/μL; sugar 45 mg/dL; protein 143 mg/dL;
TPHA pos 1:10 240, RPR pos; IgG FTA-ABS pos
53 WBC/μL; sugar 53 mg/dL; protein 87 mg/dL;
TPHA pos 1:10 240, RPR pos; IgG FTA-ABS pos
32 WBC/μL; sugar 48 mg/dL; protein 112 mg/dL;
TPHA pos 1:10 240 pos; RPR pos; IgG FTA-ABS pos
CSF tests after treatment3 WBC/μL; sugar 53 mg/dL, protein 87 mg/dL;
TPHA pos 1:5120; RPR pos; IgG FTA-ABS pos
10 WBC/μL; sugar 57 mg/dL; protein 67 mg/dL;
TPHA pos 1:2560; RPR borderline; IgG FTA-ABS pos
6 WBC/μL; sugar 55 mg/dL; protein 72 mg/dL;
TPHA pos 1:5120; RPR pos; IgG FTA-ABS pos
  • CSF, cerebrospinal fluid; FTA-ABS, fluorescent treponemal antibody absorption; MMSE, Mini Mental State Examination; neg, negative; pos, positive; RPR, rapid plasma reagin; TPHA, Treponema pallidum haemagglutination assay; WBC, white blood cells.